This is a paid press release. Contact the press release distributor directly with any inquiries.
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Record second quarter 2026 revenue increased35% to $17.1 million, compared withQ2 2025
Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding to 20%
Remaining performance obligations grew 30% year-over-year to $80.4 million
Shipped a record total 125 Deep TMS systems in Q2 2026, a 42% increase year-over-year
Raises FY 2026 revenue and EBITDA guidance
BURLINGTON, Mass. and JERUSALEM, Aug. 12, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported its second quarter 2026 financial results and provided an operational update.
Recent Financial and Operational Highlights
-
Revenue in the second quarter of 2026 increased 35% to $17.1 million, compared with $12.6 million in the second quarter of 2025.
-
Remaining performance obligations (RPOs) rose to $80.4 million as of June 30, 2026, a 30% increase compared with the same period last year.
-
Shipped a record total 125 Deep TMS™ systems during the second quarter of 2026, a 42% increase compared with the same period last year. Total installed base now stands at approximately 1,949.
-
Operating income for the second quarter of 2026 increased more than 300% to $2.4 million, compared with $0.6 million for the prior year period. Operating margin for the quarter expanded to 14% from 5% for the prior year period.
-
Adjusted EBITDA for the second quarter of 2026 increased 141% to $3.5 million, compared with $1.5 million for the prior year period. Adjusted EBITDA margin for the quarter expanded to 20% from 11% for the prior year period.
-
Net income for the second quarter of 2026 increased 34% to $2.7 million, compared with $2.0 million for the prior year period.
-
As of June 30, 2026, cash and cash equivalents and restricted cash totaled $62.4 million, an increase of approximately 6% compared with March 31, 2026.
-
Generated $6.3 million of cash flow from operations during the second quarter of 2026.
-
Continued expansion of insurer coverage for the SWIFT™ (Short-course with Intrinsic Field Targeting) accelerated Deep TMS protocol.
-
Presented real-world data in patients with comorbid post-traumatic stress disorder (PTSD) and major depressive disorder (MDD), demonstrating an 83.5% response rate in PTSD symptoms, with a mean 52% reduction in PCL-5 scores.
-
Presented the first prospective 12-month durability data for the SWIFT accelerated Deep TMS protocol at the 14th Annual Clinical TMS Society (CTMSS) Meeting, demonstrating sustained clinical improvement through one year following treatment.
-
Continued expanding the Company’s growing minority investment portfolio through strategic investments in Hopemark Health and Radial Health, with several previous portfolio investment targets indicating significant growth in patient access to care due to the growth capital afforded under the program.
